About

About Image

      About

      Bone Biologics is a publicly traded company based in Boston, MA and is focused on developing and marketing orthobiologic products. Our proprietary platform technology is NELL-1, a recombinant human protein growth factor that is essential for normal bone development. Our lead product is a NELL-1 based bone graft substitute for spine fusion, targeting the rapidly growing orthobiologics market. Our goal is to offer patients superior safety with uncompromising efficacy relative to existing technologies. NELL-1  provides specific targeted regulation over bone regeneration in the presence of targeted osteogenic cells, as both demonstrated in the lab and through the use of animal testing, unlike any other current therapy. It has been shown not to form bone when applied to non-osteogenic cells such as myoblasts (a type of embryonic progenitor cell that differentiates to give rise to muscle cells) nor does it induce adipogenesis (the formation of fat that can occur within the bone matrix often exhibited as cysts) that results in weaker bone.

      MISSION
      Our mission is to utilize the power of NELL-1 to improve clinical outcomes and reduce total health care delivery costs associated with spinal fusion. Bone Biologics is focused on bone repair and regeneration applications and is committed to exploring additional applications of the NELL-1 technology to enhance bone regeneration and repair in areas where the current options provide suboptimal patient outcomes.

      Leadership

      Leadership Image

          Leadership

          The Bone Biologics leadership team consists of some of the top leaders and innovators of orthobiologics in regenerative medicine. Not only does our leadership provide strategic oversight of the Company, they contribute to the collective advancement of the industry. This leadership is instrumental in fulfilling our mission to improve clinical outcomes and reduce health care delivery costs associated with lumbar spinal fusion.

          Products

          Products Image

          Articles

          Bone Biologic’s leading scientists have been published in notable scientific journals and publications in its field. These publications have served to highlight the work and achievements of its founders and scientific advisory board members.

          Proliferation and Osteogenic Differentiation of Mesenchymal Stem Cells Induced by a Short Isoform of NELL-1

          Pang S, Shen J, Liu Y, Chen F, Zheng Z, James A, Hsu C, Zhang H, Lee K, Wang C, Xuepeng C, Jia H, Zhang X, Soo C, Ting K. Stem Cells 2015 March: 33(3): 904-915.

          Proliferation and Osteogenic Differentiation of Mesenchymal Stem Cells Induced by a Short Isoform of NELL-1

          Pang S, Shen J, Liu Y, Chen F, Zheng Z, James A, Hsu C, Zhang H, Lee K, Wang C, Xuepeng C, Jia H, Zhang X, Soo C, Ting K. Stem Cells 2015 March: 33(3): 904-915.

          Full-length NELL-1 contains 810 aa residues (NELL-1810) plays an important role in embryologic skeletal development, the N-terminal-truncated NELL-1 isoform (NELL-1570) was expressed postnatally. Similar to NELL-1810, NELL-1570 induced MSC osteogenic differentiation. In vivo, NELL-1570 induced significant calvarial defect regeneration accompanied by increased cell proliferation. Thus, NELL-1570 has the potential to be used for cell-based or hormone-based therapy of bone regeneration.

          + Read More

          Bioactivity and circulation time of PEGylated NELL-1 in mice and the potential for osteoporosis therapy

          Biomaterials (2014) 35(24): 6614-6621.

          Bioactivity and circulation time of PEGylated NELL-1 in mice and the potential for osteoporosis therapy

          Biomaterials (2014) 35(24): 6614-6621.

          Linear PEG 5k yielded the most efficient PEGylation and the most thermally stable conjugate, linear PEG 20k resulted in the conjugate with the highest Mw and longest in vivo circulation. Compared to non-modified NELL-1, all three PEGylated conjugates showed enhanced thermal stability and each prolonged the in vivo circulation time significantly. Furthermore, PEGylated NELL-1 retained its osteoblastic activity without any appreciable cytotoxicity.

          + Read More

          Oligomerization-induced Conformational Change in the C-terminal Region of Nel-like Molecule 1 (NELL-1) Protein Is Necessary for the Efficient Mediation of Murine

          Nakamura Y, Hasebe A, Takahashi K, Iijima M, Yoshimoto N, Maturana a, Ting K, Kuroda S, Niimi T.  J. B. Chem. 289(14): 9781-9784 (2014).

          Oligomerization-induced Conformational Change in the C-terminal Region of Nel-like Molecule 1 (NELL-1) Protein Is Necessary for the Efficient Mediation of Murine

          Nakamura Y, Hasebe A, Takahashi K, Iijima M, Yoshimoto N, Maturana a, Ting K, Kuroda S, Niimi T.  J. B. Chem. 289(14): 9781-9784 (2014).

          A deletion analysis demonstrated that the C-terminal cysteine-rich region of NELL-1 is critical for the cell adhesion activity of NELL-1. Results suggest that an oligomerization-induced conformational change in the C-terminal region of NELL-1 is important for the efficient mediation of cell adhesion and spreading by NELL-1.

          + Read More

          « Newer EntriesOlder Entries »

          Investor Relations

          Investor Relations Image

              Investor Relations

              Bone Biologics was founded in 2004 by Dr. Chia Soo, MD/Vice-Chair and Professor, UCLA Hospital Dept of Orthopedic Surgery; Dr. Kang Ting DMD, DMSc/Professor, UCLA Dental School; and Dr. Benjamin Wu, DDS, PhD/Chair and Professor, UCLA Dept of Bioengineering.The Company was acquired in 2006 by MTF, the major shareholder and primary funder since the acquisition.

              Headquartered in Boston, Massachusetts, USA, Bone Biologics became a public company in September 2014 and is focused on bone repair and regeneration applications. The company is committed to exploring additional applications of the NELL-1 technology to enhance bone regeneration and repair in areas where the current options provide suboptimal patient outcomes.

              Contact

              Contact Image

                  Contact

                  General Inquiries:
                  Chris Martin
                  412.749.9299 x2
                  Chris@AtlasStories.com

                  Investor Inquiries:
                  Mark Collinson
                  714.222.5161
                  mcollinson@compass-ir.com

                  Media Inquiries:
                  Tracy Williams
                  310.824.9000 x22
                  tracy@olmsteadwilliams.com

                  For information regarding our company and/or products, please complete the form below.





                  Your Name (required)

                  Organization

                  Title

                  Email (required)

                  Phone

                  Preferred Means of Reply

                  Your Message

                  Scratch Pad
                  Parent : products 9